A new generation of truly Fc silent antibodies

mAbsolve is committed to improving the safety and effectiveness of therapeutic antibodies and Fc fusion proteins.

Forty years of Innovation

Our founders were pioneers of monoclonal antibody therapy, bringing to the clinic the first humanised antibody, the first made in CHO cells, the first bispecific and the first aglycosylated antibody.

Now we have developed a new Fc variant which is more comprehensively silenced than previous antibodies. It is able to reduce unwanted inflammatory responses from the next generation of antibody-based drugs.

Building new Partnerships

We are building partnerships with Universities, Biotech and Pharma companies to licence this new technology and make it widely available. We hope that you will be next. Please contact us if you would like to hear more.